Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant low-dose radiotherapy + vibepolimab + pucilizumab in EGFR-positive esophageal squamous cell carcinoma (ESCC-LDR-03)
ChiCTR2600124196Phase 2Recruiting
- Sponsor
- Army Specialized Medical Center
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vibepolimab and pucilizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Army Specialized Medical Center. Primary endpoints: Pathological Complete Response (pCR) and Objective Response Rate (ORR). Started May 2026; status: recruiting.
02
Drugs
vibepolimabpucilizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2600124196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124196.